Outlook Therapeutics (NASDAQ:OTLK) suspended post-Lytenava approval, with funding under pressure from looming warrants

Outlook Therapeutics, Inc. stock surged Tuesday after the company said the U.S. Food and Drug Administration accepted its resubmitted Biologics License Application, or BLA, for ONS-5010/LYTENAVA as a treatment for wet age-related macular degeneration. A BLA is the FDA application used to seek approval to market a biologic medicine. OTLK traded at $1.51, up about 30.2% from its previous close of $1.16, with intraday volume above 33.7 million shares, according to market data available in afternoon trading.

Outlook Therapeutics, Inc. shares fell sharply in after-hours trading on Dec. 31 after the U.S. Food and Drug Administration again declined to approve its ONS-5010/LYTENAVA filing for wet age-related macular degeneration. The stock closed down 15.51% at $1.58 and slid to $0.58 after hours. Nasdaq